Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

November 10, 2017: By Jon Swedien

EYLEARegeneron reported Nov. 8 that net sales of Eylea (aflibercept) in the US totaled $953 million in Q3-2017, a 12 percent increase over Q3-2016 revenues of $854 million.

Bayer commercializes Eylea outside the US. In Q3-2017, net sales of Eylea outside of the US were $564 million, compared with $471 million in the third quarter of 2016, a 20 percent increase, Regeneron said. In Q3-2017, Regeneron recognized $205 million from its share of net profit from Eylea sales outside the US, compared with $171 million in Q3-2016.

About 70 percent of Eylea sold in the US goes to treat wet age-related macular degeneration and about 25 percent goes to treat diabetic macular edema (DME), said Manisha Narasimhan, PhD, Regeneron’s head of investor relations. Narasimhan said DME represents a significant growth opportunity for Eylea because a large majority of patients are not currently using an anti-VEGF treatment.

Regeneron, based in Tarrytown, New York, posted $1.5 billion in revenues in Q3-2017, compared with $1.2 billion in Q3-2016, a 23 percent increase.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022